We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets close in 23 minutes

Predictive Oncology Inc. (POAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7800-0.0220 (-2.74%)
As of 3:36PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close0.8020
Open0.8050
Bid0.7695 x 1200
Ask0.7750 x 800
Day's Range0.7671 - 0.8108
52 Week Range0.7310 - 5.3900
Volume301,192
Avg. Volume1,416,315
Market Cap12.028M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-4.7920
Earnings DateJun 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Predictive Oncology CEO Letter to Shareholders

    EAGAN, Minn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to release the CEO’s letter to the shareholders. To our valued shareholders,I know you have watched our stock price decline steadily over the past few weeks. I am writing to assure you that there is a lot of encouraging progress to report – in other words, our company is not in the condition that the stock price might indicate. I want to take this opportunity to review where Predictive Oncology stands as of today.Our cash burn is stable and trending downward. Our revenues are stable and trending upward. Our available cash is adequate for operations and we have the ability to utilize our equity line of credit, which has a remaining amount of over $10 million.The best news is in the operational progress in our various divisions. Starting with Skyline Medical, this division is self-supporting from a cash standpoint. Sales of disposables used on previously sold machines more than cover the operating expenses of this division, and we continue to sell new machines on a regular basis, adding to future disposables revenues.Our Helomics division is coming along handsomely. We have launched a restructured clinical test offering to clinicians for ovarian cancer. The response from oncologists to this re-configured test has been excellent and we expect this effort, as well as our other tests, to be revenue generating by year end and should be able to cover the bulk of Helomics operating expenses going forward. We have made solid progress on the UPMC-Magee Women’s Hospital project and are close to completing our AI-driven models of drug response and patient outcomes. We are also finishing the sequencing of the tumors from the patients involved and have completed the “reach back” for patient outcome data (i.e. including data on what happened to the patient). The Magee Study validates our ability to sequence our tumor inventory as well as to do the reach back for patient outcomes. The acquisition and integration of the newly acquired Quantitative Medicine AI software into Helomics’ existing computer model is a major accomplishment. We have begun discussions with large Pharma companies in an effort to form major, multi-year, multi-target, milestone based strategic partnerships. We hope to make more announcements soon.Our TumorGenesis division has not been resting on its’ laurels. We will be introducing our Ovarian Cell Line Media at the BIO-Europe Conference. This media will allow researchers to isolate and successfully culture ovarian cancer cells that have previously not been cultured. Under the NCI Prevent Cancer Program, TumorGenesis, Cornell Medical and Helomics will coordinate with and seek funding for this program to help identify the best culture media for the studying of mutations that increase the risk of ovarian and breast cancers as well as other types of cancers. TumorGenesis is registering with the U.S. government as a contractor for developmental work in cancer cell capture and screening of compounds for the prevention and treatment of cancer. TumorGenesis Discovery Kits will also launch at the BIO-Europe conference. These kits will allow researchers to study and tag target cancer cells as well as normal cells often associated with tumors and let pathologists screen approved drug therapies across isolated and properly identified ovarian cancer samples from patients.Last, but certainly not least, is Soluble Biotech. We have moved this division into a new Research Park located in Birmingham, Alabama. This new facility effectively quadruples our Soluble’s office and research space. This state of the art company provides optimized FDA-approved formulations for vaccines, antibodies and other protein therapeutics in a faster and lower cost basis to its customers. In addition, the company recently purchased and installed a suite of new research equipment that enables protein degradation studies which is a new and substantial line of business for the company. Our investment in new equipment, combined with our proprietary existing equipment, expands the company’s capabilities to include temperature-controlled humidity chamber analysis, temperature-controlled photo-stability analysis, differential scanning calorimetry, viscometry analysis, UV/Vis spectroscopy analysis, High Performance Liquid Chromatography (HPLC), a state-of-the-art automated dynamic laser light scattering system (DLS), free flow particle microscopic analysis, circular dichroism analysis, electron microscopy and high resolution mass spectrometry. Soluble Biotech is also planning to begin the development of an FDA-approved GMP facility to further support pharmaceutical needs. We have already secured a sizable contract and we are bidding on several more. I expect Soluble Biotech to be generating revenues by the end of the year.As you can see, a lot is happening. Much is occurring under the radar. Much doesn’t make for a press release. However, don’t be discouraged by the lack of “blockbuster” announcements. We are moving forward rapidly and we expect the fourth quarter to be eventful. I will make myself available to shareholders who may wish to speak with me.Sincerely,Carl Schwartz CEO Predictive Oncology.About Predictive Oncology, Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. TumorGenesis, Inc. a wholly owned subsidiary specializes in media’s that help cancer cells grow and retain their DNA/RNA and proteomic signatures providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. In addition, TumorGenesis is developing a ‘biomarker discovery’ kit and service for life science, pharmaceutical and biotech companies, and research institutions. Its products are sold on-line as well as through a global distributor; US Biologicals Corporation: http://www.usbio.net. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Biotech brings transformational technology to formulation development for protein-based pharmaceutical and vaccines. In addition, our solubilization & stability technology supports fundamental protein research at academic, pharmaceutical and government laboratories. To learn more, please visit: https://solublebiotech.com.Cautionary Statement Regarding Forward-Looking StatementsCertain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.Investor Relations Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

  • What Can We Conclude About Predictive Oncology's (NASDAQ:POAI) CEO Pay?
    Simply Wall St.

    What Can We Conclude About Predictive Oncology's (NASDAQ:POAI) CEO Pay?

    This article will reflect on the compensation paid to Carl Schwartz who has served as CEO of Predictive Oncology Inc...

  • GlobeNewswire

    Predictive Oncology Secures License for an Additional 71 Unique Ovarian Cancer Cell Lines from Ximbio, Cancer Research UK’s Premier Reagents Distributor

    Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from Ovarian Cancer Patients.EAGAN, Minn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- TumorGenesis, a division of Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has received a license for an additional 71 unique ovarian cancer cell lines and now has a total of 96 unique patient derived cells all acquired from ovarian cancer patients. These cell lines were licensed from the English company, Ximbio, the world’s largest non-profit dedicated to life science reagents of all kinds. Richard Gabriel, President of TumorGenesis, commented, “It is remarkable that the UK cancer researchers using the same media mixes now being offered by TumorGenesis for researchers around the world, independently isolated, and identified another unique set of ovarian cancer cells from patients. Adding these 71 cell lines to our existing 25 cell lines (11 of the first 25 are representative of about 95% of ovarian tumors) adds a powerful new resource for researchers. The media used to grow the novel and unique ovarian cancer cell lines, licensed by Predictive Oncology and its partner, GLG Pharma, is able to retain 95%+ of the cell’s DNA and RNA as well as crucial proteomic signatures. Our media will be used for the isolating and growing of ovarian cancer cells, which are often found in the ‘ascites’ fluid located in the abdomen of women with advanced ovarian cancer. Ovarian cells cultured from these ascites fluids are notoriously difficult to work with and when using standard media mixes are often prone to failure. In additional, these cell lines, generally speaking, are not representative of the patient’s unique ovarian cancer.”Experiments are the foundation of preclinical research and development. Waste from research using unvalidated media and reagents cost the pharmaceutical companies over $28 billion in 20151. Also, irreproducibility rates in preclinical experiments exceed 50%, costing the industry nearly an additional $48 billion annually2.“This new media will allow researchers around the world to isolate and culture ovarian cancer cell types and, in addition, culture them reproducibly to find new targets for the diagnostics, treatment, or any other needed studies on the close interrelationship of ovarian cancer tumor populations and how they are able to fool a patient’s immune system’,” Mr. Gabriel highlighted.12015-Freedman et al-The Economics of Reproducibility in Preclinical Research; PLOS Biology DOI:10.1371/journal.pbio.1002165 June 9, 2015 2Endpoint News, June 8, 2020; https://endpts.com/sp/48-billion-is-lost-to-avoidable-experiment-expenditure-every-year/Researchers around the world can contact US Biological Corporation or Richard Gabriel at TumorGenesis for information on these new media(s) and the availability of ovarian cancer cells for research.About Precision Oncology, Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.TumorGenesis, Inc. a wholly owned subsidiary specializes in media’s that help cancer cells grow and retain their DNA/RNA and proteomic signatures providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. In addition, TumorGenesis is developing a ‘biomarker discovery’ kit and service for life science, pharmaceutical and biotech companies, and research institutions. Its products are sold on-line as well as through a global distributor; US Biologicals Corporation: http://www.usbio.net.Cautionary Statement Regarding Forward-Looking Statements Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.Investor Relations Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

  • GlobeNewswire

    Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern Time

    EAGAN, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor Conference, on Wednesday, September 02, 2020 3:40 PM Eastern Time. A live webcast of the presentation will be available to the public at https://www.webcaster4.com/Webcast/Page/2019/36691. The webcast will be archived for 90 days following the live presentation.About Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.   Forward-Looking StatementsCertain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.Investor Relations Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

  • GlobeNewswire

    Soluble Biotech Announces First Contract with a Major Pharmaceutical Company for Protein Expression and Solubility Studies

    EAGAN, Minn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Soluble Biotech division, a provider of soluble and stable formulations for proteins, just received its first substantial contract from a major pharmaceutical company since being acquired by Predictive Oncology in May 2020. The project involves protein expression followed by solubility studies, areas of significant expertise within Soluble Biotech. “Our first contract is a major milestone and validates our recent move into a new, larger facility”, says Dr. Larry DeLucas, former NASA astronaut and founder of Soluble Biotech. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies. With our first contract on the books, and expanded capacity, the future is bright. We are currently negotiating several additional contracts with biotechnology and pharmaceutical companies.”About Soluble Biotech, Inc.Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Biotech brings transformational technology to formulation development for protein-based pharmaceutical and vaccines. In addition, our solubilization & stability technology supports fundamental protein research at academic, pharmaceutical and government laboratories. To learn more, please visit: https://solublebiotech.comAbout Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.Forward-Looking StatementsPortions of the narrative set for this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.These factors include, in addition to those mentioned elsewhere herein: * We may not be able to continue operating without additional financing; * Current negative operating cash flows; * The terms of any further financing, which may be highly dilutive and may include onerous terms; * Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources; * Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; * Risks related to the transaction with Quantitative Medicine including: 1) possible failure to realize anticipated benefits of the transaction; 2) costs associated with the acquisition may be higher than expected; 3) the transaction may result in the disruption of our existing businesses; and 4) distraction of management and diversion of resources; * Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property; * The impact of competition; * Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology; * Inability to attract or retain qualified senior management personnel, including sales and marketing personnel; * Risk that we never become profitable if our product is not accepted by potential customers; * Possible impact of government regulation and scrutiny; * Unexpected costs and operating deficits, and lower than expected sales and revenues, if any; * Adverse results of any legal proceedings; * The volatility of our operating results and financial condition; * Management of growth; * Material and adverse effects of the COVD-19 pandemic, including impact on a significant supplier; a reduction in on-site staff at several of our facilities, resulting in delayed production and less efficiency; impact on sales efforts; impact on accounts receivable and terms demanded by suppliers; and possible impact on financing transactions; and, * Other specific risks that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov.Investor Relations Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

  • GlobeNewswire

    Predictive Oncology’s Skyline Medical Sells 8 STREAMWAY® Systems to a Large University Hospital Organization in Virginia; 13 STREAMWAY® Systems Sold Halfway Into Q3 2020

    EAGAN, Minn., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has completed the sale of 8 STREAMWAY systems to a large university hospital organization in Virginia for a new surgical center.  The hospital system already has 2 STREAMWAY systems currently in use. The sale is expected to generate approximately 4,000 procedures annually. The company has now sold 13 STREAMWAY systems during Q3 2020.About Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.Forward-Looking StatementsPortions of the narrative set for this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.These factors include, in addition to those mentioned elsewhere herein: * We may not be able to continue operating without additional financing; * Current negative operating cash flows; * The terms of any further financing, which may be highly dilutive and may include onerous terms; * Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources; * Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; * Risks related to the transaction with Quantitative Medicine including: 1) possible failure to realize anticipated benefits of the transaction; 2) costs associated with the acquisition may be higher than expected; 3) the transaction may result in the disruption of our existing businesses; and 4) distraction of management and diversion of resources; * Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property; * The impact of competition; * Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology; * Inability to attract or retain qualified senior management personnel, including sales and marketing personnel; * Risk that we never become profitable if our product is not accepted by potential customers; * Possible impact of government regulation and scrutiny; * Unexpected costs and operating deficits, and lower than expected sales and revenues, if any; * Adverse results of any legal proceedings; * The volatility of our operating results and financial condition; * Management of growth; * Material and adverse effects of the COVD-19 pandemic, including impact on a significant supplier; a reduction in on-site staff at several of our facilities, resulting in delayed production and less efficiency; impact on sales efforts; impact on accounts receivable and terms demanded by suppliers; and possible impact on financing transactions; and, * Other specific risks that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov.Investor Relations Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

  • GlobeNewswire

    Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, ‘Can We Cure Cancer with Artificial Intelligence?’

    LOS ANGELES, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE!, a lively podcast and interview forum that brings together a broad roster of technology, business and thought leaders from a wide range of software companies and startups. The broadcast, titled ‘Can We Cure Cancer With Artificial Intelligence?’, is available for on-demand viewing on the DojoLIVE! website.As noted during the interview, Collins possesses a passion for applying science to build high-tech life-science products and services that impact the search for new medicines. He feels that Helomics, a division of Predictive Oncology, is uniquely positioned to deliver on this goal.Helomics aims to improve outcomes for the cancer patients of today and in the future by harnessing the power of the patient’s own living tumor. The company uses its unique clinically validated Tumor Drug Response Profiling (TDRP) platform to generate a comprehensive profile of the patient tumor to guide the oncologist in individualizing treatment. In use for 15+ years, this platform has generated drug response and genomic profiles on over 150,000 tumors – the largest knowledgebase of its kind in the world.Helomics is leveraging this unique TDRP platform and huge knowledge base to pioneer the development of AI-driven models of tumor drug response and outcome that, in partnership with pharmaceutical companies, will enable lower cost, faster and smarter discovery of new therapies. Furthermore, once validated, these AI-models will be used as clinical decision support tools to help clinicians individualize cancer treatment with current therapies.About Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs.Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales on five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.Forward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.Corporate CommunicationsInvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

  • GlobeNewswire

    Predictive Oncology Reports Second Quarter 2020 Financial Results, Provides Business Update

    Increases Readiness for Commercialization with Expanded Portfolio of Solutions for Precision Medicine NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2020 and provided a business update.Financial and Business Highlights of Q2 and Recent Developments * Secured first commercial sale of its novel ovarian cancer cell media for cancer cells collected from patient derived samples through its TumorGenesis division * Completed the acquisition of Quantitative Medicine (“QM”), a biomedical analytics and computational biology company (July 2020), in an all-stock transaction valued at approximately $1.8 million * Completed an asset purchase agreement to acquire Soluble Therapeutics and its HSC™ Technology along with BioDtech Inc. * Refreshed Board of Directors with appointment of three new independent directors * Strengthened balance sheet with recent equity offerings.   * Management anticipates a need to raise additional capital to support operations and near-term debt repayments“During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” commented Dr. Carl Schwartz, Predictive Oncology CEO. "This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare outcomes for cancer patients. Our unique media significantly expands the number of ovarian cancer cell types that can be studied representing nearly 95% of all ovarian cancers, many of which have never been cultured before now, and reduces waste in cancer research.”“Our acquisitions of Soluble Therapeutics and BioDtech position us with next level capabilities that we believe will materially advance our progress towards developing new targeted therapies in collaborations with pharmaceutical companies and enable meaningful expansion of revenue opportunities,” added Dr. Schwartz. “Soluble Therapeutics assets will help us to provide the best formulation with the highest concentration and the most stable solution for protein and peptide-based drugs while the acquisition of BioDtech gives us governance over its testing solution for unmasking endotoxins. Together, we believe these acquisitions will substantially advance the discipline of precision medicine and accelerate our pursuit of monetizing our full portfolio of assets.”Dr. Schwartz continued, “We also completed our acquisition of QM in early 2020, bringing its proven, machine learning platform, CoRE, into our portfolio of assets in our Helomics business and equipping us with a framework for an end-to-end solution for precision medicine. We are encouraged by the emerging opportunities this opens for us to further revolutionize AI-driven predictive modeling that can be used to accelerate the development of personalized patient treatments.”   “Our Helomics business continues to make solid progress with our CancerQuest 2020 initiative and our collaboration with UPMC Magee Hospital to build AI-driven predictive models for the treatment of ovarian cancer,” added Dr. Schwartz. “Thus far, we have received outcome data, completed the second phase of sequencing and have begun the process to build our AI-model. We are on track to complete the study and have our first AI-driven model in accordance with our workplans, despite a later start date that was triggered by a delay in funding resulting from the COVID-19 pandemic. We expect to have our first AI-driven model completed in the second half of 2020. Just as important, we have been ramping up our commercial outreach activities with large pharma companies to build a pipeline of targeted opportunities ahead of model completion.”Dr. Schwartz concluded, “We further bolstered our liquidity position with approximately $4.6 million in gross proceeds from a registered direct offering of common stock, the exercise of warrants and the issuance of additional warrants. Although we still have significant short-term debt obligations, the equity offerings demonstrate investor confidence, extend our cash runway and provide working capital to continue our pursuit of developing commercially viable solutions for large pharma. From a governance perspective, we refreshed our board operations with the appointment of three new independent directors, who collectively have extensive industry, financial and business development experience and a rich network of industry contacts that we believe will be extremely advantageous as we execute the next steps in our business plan.”Second Quarter 2020 Financial ResultsRevenues were $183,000 compared with $286,000 for the second quarter of 2019. Revenues in both years were primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY units, of which 1 unit and 7 units were sold in the three months ended June 30, 2020 and 2019, respectively.Gross margin was 53% in the second quarter of 2020 compared with 59% in the 2019 period. The decrease was due to higher costs on lower revenue in the current period compared to the prior year period. General & administrative expenses decreased 3% to $3.2 million in the second quarter of 2020 as a result of lower costs related to share-based compensation. Operations expenses decreased to $521,000, compared with $1.3 million in the second quarter of 2019.Net loss was $3.6 million, inclusive of other income of $1.3 million related to the revaluation of equity method investments and gains on elimination of notes outstanding, and interest and dividend income, compared with net income of $1.5 million for the second quarter of 2019. The second quarter of 2020 includes a gain on the revaluation of cash advances to Helomics of $1.2 million and a gain of $6.2 million on a revaluation of equity method investment. OutlookManagement continues to focus its resources on the Helomics and TumorGenesis divisions and the Company’s primary mission of applying artificial intelligence to precision medicine, drug discovery and the mediums used to replace rats and mice in preliminary cancer studies. Management reaffirms that it is focusing the majority of its resources on maximizing opportunities within the Company’s precision medicine business.About Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.Forward-Looking StatementsPortions of the narrative set for this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.These factors include, in addition to those mentioned elsewhere herein: * We may not be able to continue operating without additional financing; * Current negative operating cash flows; * The terms of any further financing, which may be highly dilutive and may include onerous terms; * Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources; * Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; * Risks related to the transaction with Quantitative Medicine including: 1) possible failure to realize anticipated benefits of the transaction; 2) costs associated with the acquisition may be higher than expected; 3) the transaction may result in the disruption of our existing businesses; and 4) distraction of management and diversion of resources; * Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property; * The impact of competition; * Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology; * Inability to attract or retain qualified senior management personnel, including sales and marketing personnel; * Risk that we never become profitable if our product is not accepted by potential customers; * Possible impact of government regulation and scrutiny; * Unexpected costs and operating deficits, and lower than expected sales and revenues, if any; * Adverse results of any legal proceedings; * The volatility of our operating results and financial condition; * Management of growth; * Material and adverse effects of the COVD-19 pandemic, including impact on a significant supplier; a reduction in on-site staff at several of our facilities, resulting in delayed production and less efficiency; impact on sales efforts; impact on accounts receivable and terms demanded by suppliers; and possible impact on financing transactions; and, * Other specific risks that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov.Investor Relations Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com\-- Tables Follow – PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2020 December 31, 2019  (unaudited) (audited) ASSETS       Current Assets:       Cash and Cash Equivalents$3,394,078  $150,831  Accounts Receivable 272,493   297,055  Inventories 235,368   190,156  Prepaid Expense and Other Assets 426,704   160,222  Total Current Assets 4,328,643   798,264          Fixed Assets, net 2,409,721   1,507,799  Intangibles, net 3,539,597   3,649,412  Lease Right-of-Use Assets 1,528,150   729,745  Goodwill 15,690,290   15,690,290  Total Assets$27,496,401   22,375,510          LIABILITIES AND STOCKHOLDERS' EQUITY       Current Liabilities:       Accounts Payable$2,449,046  $3,155,641  Notes Payable – Net of Discounts of $282,099 and $350,426 4,412,377   4,795,800  Accrued Expenses 2,649,160   2,371,633  Derivative Liability 4,629,570   50,989  Deferred Revenue 38,582   40,384  Lease Liability 473,043   459,481  Total Current Liabilities 14,651,778   10,873,928          Lease Liability – Net of current portion 1,055,107   270,264  Other long-term liabilities 98,358   -  Total Liabilities 15,805,243   11,144,192          Stockholders’ Equity:       Preferred Stock, 20,000,000 authorized inclusive of designated below       Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 and 79,246 shares outstanding 792   792  Series D Convertible Preferred Stock, $.01 par value, 3,500,000 shares authorized, 0 and 3,500,000 outstanding -   35,000  Series E Convertible Preferred Stock, $.01 par value, 350 shares authorized, 0 and 258 outstanding -   3  Common Stock, $.01 par value, 100,000,000 shares authorized, 13,190,787 and 4,056,652 outstanding 131,908   40,567  Additional paid-in capital 102,163,864   93,653,667  Accumulated Deficit (90,605,406)  (82,498,711)         Total Stockholders' Equity 11,691,158   11,231,318          Total Liabilities and Stockholders' Equity$27,496,401  $   22,375,510  PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS (Unaudited)                                                                                                                                                                                                                                                                                           Three Months Ended      Six Months Ended  June 30,     June 30,    2020   2019   2020   2019  Revenue$182,784  $286,151  $477,727  $541,392  Cost of goods sold 85,261   118,390   177,918   192,106  Gross margin 97,523   167,761   299,809   349,286           General and administrative expense 3,211,817   3,310,368   6,040,293   4,808,314  Operations expense 521,116   1,271,258   1,069,869   1,737,824  Sales and marketing expense 133,015   685,029   397,424   1,239,245  Total operating loss (3,768,425)  (5,098,894)  (7,207,777)  (7,436,097)          Gain on revaluation of cash advances to Helomics          -   1,222,244                               -                  1,222,244  Other income 52,965   (3,223)  52,968   50,209  Other expense (729,837)  (607,343)  (1,846,912)  (1,157,711) Gain (loss) on derivative instruments (422,081)  (211,940)  (394,974)  (231,348) Gain on notes receivables associated with asset purchase                1,290,000                                -                  1,290,000                                -  Loss on equity method investment -   -   -   439,637  Gain on revaluation of equity method in investment                                -   6,164,260                                 -                  6,164,260  Net income (loss)$(3,577,378) $1,465,104  $(8,106,695) $(1,828,080) Deemed dividend on Series E Convertible Preferred Stock                                -      20,398                                  -                       20,398  Net income (loss) attributable to common shareholders per common shares-basic and diluted$(3,577,378) $            1,444,706  $        (8,106,695) $          (1,848,478)          Gain (loss) per common share basic$  (0.36) $  0.49  $  (1.10) $ (0.81) Gain (loss) per common share diluted   (0.36)    0.24     (1.10)    (0.81)          Weighted average shared used in computation - basic 9,838,152       2,960,937                              7,362,240               2,274,754  Weighted average shared used in computation - diluted 9,838,152    6,007,078   7,362,240   2,274,754

  • GlobeNewswire

    Predictive Oncology Issues Letter to Shareholders

    Annual Meeting of Stockholders to be Held on September 3, 2020NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today issued a letter to shareholders discussing the Company’s recent accomplishments and voting recommendations from its Board of Directors for two proposals that are scheduled for shareholder vote on September 3, 2020. Dear Fellow Shareholders,Predictive Oncology is committed to executing our strategic vision to develop and commercialize an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value for our shareholders. Over the last six months we have been diligently assembling a portfolio of assets and aligning our capital and governance structures to help us achieve this vision.At our annual meeting on September 3, 2020, we are asking you to approve two important compensation-related proposals – repricing stock options for executives and key employees (but excluding director options), and an increased share reserve for the stock incentive plan. Management and the Board considered these proposals carefully before recommending them for your approval, and we need your vote FOR these proposals. Approval is critical as we expand upon our considerable recent business accomplishments and enhance shareholder value by attracting and retaining talented management.Recent Accomplishments * Completed acquisition of Quantitative Medicine. In July we completed our acquisition of QM, a biomedical analytics and computational biology company. This acquisition equips us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing. By integrating QM’s proven machine learning platform, CoRE, with our proprietary database of drug response and genomics profiles we believe we can revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers and will be able to more quickly understand how specific types of tumors react to cancer drug therapies. We expect to offer this new capability to our pharmaceutical company customers in revenue generating projects later this year. * Completed acquisition of Soluble and BioDtech. In June we completed our acquisition of Soluble Therapeutics and BioDtech, thereby expanding our precision medicine revenue and monetization prospects in a meaningful way. The Soluble Therapeutics assets increase our capabilities to predict and provide the best formulation with the highest concentration and the most stable solution for protein and peptide-based drugs in providing services to the pharmaceutical and biotech industries. Our acquisition of BioDtech gives us ownership of BioDtech’s successfully developed test used to ‘unmask’ endotoxins, which allows a monitoring physician to perhaps change the strategy of treatment or treat the patient with antibiotics. These acquisitions expand our opportunities within precision medicine. * First commercial sale of novel ovarian cancer media. In the second quarter our TumorGenesis business achieved a major milestone with the first order of our unique ovarian cancer cell culture media for cancer cells collected from patient derived samples (PDx) to a top-rated medical university in New England. This new media allows researchers around the world to isolate and then culture ovarian cancer cell types and culture them reproducibly to find new targets for treatment, diagnostics or other studies on the close interrelationship of ovarian cancer tumor populations and how they are able to fool a patient’s immune system. * Helomics nearing commercialization of revenue-generating services. Helomics, our flagship precision medicine and AI division, continues its strong progress on CancerQuest2020, its collaborative project with UPMC Magee Women’s Hospital to build an AI-driven predictive model of ovarian cancer. In addition, there is continued progress with Genomics England in the UK to build an AI model or ovarian cancer to be used for clinical decision support for patients. We expect completion of the models in late Q3 and are pursuing in parallel commercial discussions to use these ovarian cancer AI-models in revenue generating projects with Pharmaceutical companies in Q4 and Q1-2021. Furthermore, we expect the recent acquisition of and integration of Quantitative Medicine’s CoRE platform to drive additional revenue generating projects in the same period. Helomics clinical testing for ovarian cancer has continued throughout the COVID-19 pandemic and we are continuing outreach efforts to clinicians to drive more testing revenue. * Strengthened balance sheet with capital raise, cash from warrants and restructuring of debt. During the second quarter we raised $4.4 million in aggregate gross proceeds through a registered direct offering and the exercise of existing warrants. In addition, I personally reinforced my commitment to our mission when I exchanged $2.1 million of Predictive Oncology notes that I held for additional common stock in the company. Through these actions, we significantly strengthened and simplified our balance sheet and created additional runway to execute our vision. * Restructured board of directors with appointment of three new directors. In July, we reconstituted our board of directors with the appointment of Dr. Nancy Chung-Welch, Ph.D., Mr. Charles L. Nuzum, CPA and Mr. Greg St. Clair. Each of these members brings a wealth of knowledge, experience and thought leadership that are highly valuable. Collectively, these appointments significantly elevate our depth in the areas of new business development, executive leadership and financial acumen and demonstrate our commitment to aligning our board’s expertise with our strategic objectives to drive increased value for our shareholders.Annual Meeting ProposalsAt our Annual Meeting on September 3, 2020 you are being asked to approve a number of proposals that are described in our proxy statement that we filed with the Securities and Exchange Commission on July 29, 2020 and have mailed to our stockholders. Two of the proposals are vital to retaining and attracting top talent aligned with executing our corporate strategy such that we can scale and grow our business and achieve profitability.  Proposal No. 3: Approval of Repricing Stock Options Held By Officers and Employees.The Board has determined that adverse changes in the market price of the Company’s common stock since the Eligible Options were granted could materially interfere with the Company’s efforts to retain the service of its existing officers and employees. In Proposal No. 3, Predictive is seeking approval of a one-time repricing of all stock options outstanding under the Company’s Amended and Restated 2012 Stock Incentive Plan held by current officers or employees of the Company which have an exercise price higher than $1.54 per share, but excluding stock options granted for service on the Board of Directors. More specifically, the proposal requests stockholder approval to change the exercise price of eligible options to $1.54 per share, equal to the closing sale price of the common stock on July 1, 2020, the day before the Board approved the repricing.The Board recommends the option repricing to encourage an increasing alignment of their interests with those of the Company’s stockholders and their stake in the long-term performance and success of the Company. When the market price for the Company’s common stock is significantly below the applicable exercise price of an option (often referred to as “underwater” or “out-of-the-money”), for example, the Board believes that the option holder is not likely to exercise that option and will not have the desired incentive that the option was intended to provide.Please note: * When the Board approved the repricing, it excluded the stock options that were granted to the directors for their service.   * In considering the repricing of my stock options that I hold as CEO, the Board noted that I received most of those option in lieu of cash salary for nearly two years, which I was willing to accept to accommodate the cash needs of the Company.Proposal No. 4: Increase in Reserve in Stock Incentive Plan. The Company does not possess enough options in its stock incentive option plan to incentivize valued employees currently working hard to bring success to Predictive and align their incentives with our shareholders. It is also critical to have a large enough share reserve under the plan to attract prospective employees to our organization. In order to meet its business and growth objectives, the company will need to hire talented additional management and operating personnel.In Proposal No. 4, Predictive is requesting stockholder approval to increase the share reserve by 750,000 shares, to a total of 1,750,000 shares. Currently, options to purchase 830,488 shares of common stock are subject to outstanding stock options under the Restated Plan. In determining the amount of the increase in the Restated Plan, the Predictive Board carefully considered its intention to grant further equity awards to current and future executive officers and key employees and directors. The Restated Plan also eliminates certain limitations on individual awards that are no longer required under applicable tax laws.The Board believes that approval of Proposal No. 4 is in the best interests of Predictive and its stockholders because the availability of an adequate number of shares reserved for issuance is important in attracting, retaining and motivating employees, consultants and directors in order to achieve the company’s long-term growth and profitability objectives.We believe that adopting these measures will give Predictive the ability to attract and retain the high-quality professionals we need to achieve our strategic vision and create value for shareholders. Accordingly, management is asking shareholders to approve the proposal to reprice options (Proposal 3) and approve the proposal to amend and restate the company’s 2012 stock incentive plan (Proposal 4).We remain open and available to speak with any of our fellow shareholders as you make your decisions and, again, thank you for your support.Dr. Carl Schwartz Chief Executive OfficerAbout Predictive Oncology Inc.Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.Forward-Looking StatementsPortions of the narrative set for this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.These factors include, in addition to those mentioned elsewhere herein: * We may not be able to continue operating without additional financing; * Current negative operating cash flows; * The terms of any further financing, which may be highly dilutive and may include onerous terms; * Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources; * Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; * Risks related to the transaction with Quantitative Medicine including: 1) possible failure to realize anticipated benefits of the transaction; 2) costs associated with the acquisition may be higher than expected; 3) the transaction may result in the disruption of our existing businesses; and 4) distraction of management and diversion of resources; * Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property; * The impact of competition; * Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology; * Inability to attract or retain qualified senior management personnel, including sales and marketing personnel; * Risk that we never become profitable if our product is not accepted by potential customers; * Possible impact of government regulation and scrutiny; * Unexpected costs and operating deficits, and lower than expected sales and revenues, if any; * Adverse results of any legal proceedings; * The volatility of our operating results and financial condition; * Management of growth; * Material and adverse effects of the COVD-19 pandemic, including impact on a significant supplier; a reduction in on-site staff at several of our facilities, resulting in delayed production and less efficiency; impact on sales efforts; impact on accounts receivable and terms demanded by suppliers; and possible impact on financing transactions; and, * Other specific risks that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov.Investor Relations Contact:Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

  • ACCESSWIRE

    LD Micro Announces Preliminary List of Presenters for the LD-500

    LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.